VEGF基因表达及微血管密度与DukesA和B期大肠癌预后的关系

来源 :上海医药 | 被引量 : 0次 | 上传用户:superdog22
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的研究Dukes A和B期大肠癌标本中VEGF基因表达及微血管密度与预后的关系。方法62例DukesA和B期大肠癌手术切除标本,采用RT-PCR法测定肿瘤组织中hVEGF165mRNA表达,以Westen蛋白印迹测定hVEGF蛋白表达,并测定标本微血管密度。所有患者接受5年以上随访。结果在随访期内出现局部复发或远处转移的患者与无复发或转移的患者相比,其VEGF基因表达及微血管数存在显著性差异。结论通过测定肿瘤标本中VEGF基因表达及微血管数可能预测Dukes A和B期大肠癌局部复发或远处转移的危险性。 Objective To investigate the relationship between VEGF gene expression, microvessel density and prognosis in Dukes A and B stage colorectal cancer specimens. Methods Sixty-two Dukes A and B stage colorectal cancer specimens were resected. The expression of hVEGF165 mRNA was detected by RT-PCR. Western blot was used to measure the expression of hVEGF protein and the microvessel density was measured. All patients received more than 5 years of follow-up. Results There were significant differences in VEGF gene expression and microvessel count between patients with local recurrence or distant metastasis and patients without recurrence or metastasis during the follow-up period. Conclusion It is possible to predict the risk of local recurrence or distant metastasis of Dukes A and B colorectal cancer by measuring VEGF gene expression and microvessel number in tumor specimens.
其他文献
中图分类号:R978.1文献标识码:B文章编号:1006-1533(2007)08-0378-02  替吉环素(tigecycline,GAR-936,TygacilTM)是首个被美国FDA批准临床使用的甘氨酰四环素类抗生素,用来治疗各种复杂性腹腔内感染(complicated intra-abdominal infections,cIAI)、复杂性皮肤和皮肤结构感染(complicated sk
期刊
目前,提供专利申请专业化法律服务的中介机构主要有专利事务所、律师事务所.由于专利申请是一项很专业的法律实务操作,没有受过专门训练者提交的申请会由于各种原因被国家知
期刊
目的 观察慢病毒介导的shRNA沉默mcl-1基因对食管癌细胞生长作用以及化疗敏感性影响。方法 利用已构建的携带mcl-1-shRNA的慢病毒载体lenti-mcl-1-shRNA感染食管癌细胞EC9706